BTS -Program

Table of Contents Letter from Organizer............................................................................................ 4 BTS Organizational Committee ...................................................................... 5 General Information ......................................................................................... 6-7 Faculty ...................................................................................................................... 8-9 Surgical Schedule - Day 1 ............................................................................ 8-9 Non Surgical Schedule - Day 1 ................................................................. 10-11 Surgical Schedule - Day 2 ........................................................................... 12-13 Non Surgical Schedule - Day 2 ................................................................ 14-15 Surgical Schedule - Day 3 ................................................................................ 16 Non Surgical Schedule - Day 3 ............................................................... 17-18 Thank You To Our Sponsors ...................................................................... 19-26 Faculty Biographies ..................................................................................... 26-44 Exhibitor Floor Plan ............................................................................................ 45 Note Pages ....................................................................................................... 46-56

Words of Welcome On behalf of the entire BTS New York team, we are honored you have joined us on Time Square in New York City for the inaugural Beauty Through Science Meeting in the United States. Beauty Through Science Stockholm was created by Per Heden, MD, in 2002 and has gradually grown to host more than a 1000 participants from nearly 50 countries. The BTS Stockholm meeting has established itself as one of the most renowned and appreciated aesthetic medical meetings in the world. As a faculty member numerous times, BTS Stockholm became mine and many of my colleagues favorite meeting. The spirit and energy of the meeting in Stockholm has always been unique and very special. As faculty, this meeting always just feels like we are sharing our ideas with our friends. The exchange of ideas with all of the participants, the highly engaging discussion panels, and accessibility of all the faculty to continue the dialogue beyond the sessions has made this meeting a favorite of everyone. Ultimately, Dr. Heden and myself decided to join forces and together continue the legacy in Stockholm, but also share this same high quality meeting in the United States – Beauty Through Science New York! This meeting has been called the meeting of “KOLs for KOLs” which simply stated means that this meeting is packed with many of the world’s top educators, all assembled to bring you a one-of-a-kind, high level scientific meeting encompassing the many facets of aesthetic medicine in both the non-surgical and surgical arena. Our well-published and highly respected faculty brings to each of you their vast knowledge - always focused on science – but also sharing their vast experience with practical applications that can be immediately incorporated into your practice. Shino Bays, MD and Patricia Ogilvie, MD put together an amazing agenda for the non-surgical portion of the meeting. You won’t want to miss the 2 cc challenge. William P Adams, MD along with Per and myself created the surgical program – this year focused on facial and breast aesthetic surgery. Saturday session is filled with “Look-Live” surgeries all day long covering 15 surgical procedures by some of the world’s best surgeons.

We hope you enjoy the first meeting of BTS-New York. We invite you to share your experience here in New York with your colleagues and hope to see you again next year. Next year, the surgical program will focus on breast and body surgery – you won’t want to miss it! Shino, Patricia and their team will undoubtedly develop a one-of- a-kind, don’t miss program for the non-surgical sessions as well.

Thank you again and enjoy your meeting.

Brad Calobrace BTS New York Chair

BTS Organizational Committee

BTS President & Chair M. Brad Calobrace, MD, FACS

Per Hedén, MD

William P. Adams Jr. MD

BTS Co-Chair

Surgical Faculty Director

Patricia Ogilvie, MD

Shino Bay Aguilera, DO Non-Surgical Faculty Director

Alona Gellerman CEO of BTS Stockholm

Non-Surgical Faculty Co-Director

Nickoli Neville COO of BTS New York

Jacqueline Gantt Marketing & Design

Jared Rohrer

Director of Digital Content

General Information

Venue

Liability

Marriot Marquis 1535 Broadway, New York, NY 10036

The BTS Congress team cannot accept liability for personal accidents, loss or damage to private property of participants, either during or directly arising from the BTS 2022 congress. Participants are expected to make their own arrangements with respect to health and travel insurance.

Registration Desk Hours

Wednesday, Nov 30 - 4:30 pm - 7:00 pm Thursday, Dec 1 - 7:30 am - 6:30 pm Friday, Dec 2- 7:30 am - 6:30 pm Saturday, Dec 3 - 7:30 am - 6:30 pm Exhibition Hours Thursday, Dec 1 - 7:30 am - 6:30 pm Friday, Dec 2- 7:30 am - 6:30 pm Saturday, Dec 3 - 7:30 am - 6:30 pm

Mobile Phones

As a courtesy to all presenters and attendees, please turn off notifacations on your mobile phone while attending sessions.

Recording Policy Recording (photographic, video and audio) of sessions is strictly prohibited. Violators will be banned from future BTS congresses.

Social Media All participants are encouraged to join the online conversation to get the most out of the congress. Catering Refreshments and lunch will be provided in the exhibition area during official catering breaks. Congress Admission Badge Admission to BTS 2022 is by badge only. Carrying the badge is mandatory for all participants. No one will be allowed admission to sessions, exhibitor area or social events without a badge.

FB: @BeautythroughScience IG: @BeautythroughScience

The official hashtags for congress are: #BeautythroughScience and #BTSNYC

Interacting by Smartphone

We encourage delegates to ask questions to the BTS faculty during all sessions. To be able to interact, you need your tablet, laptop or smartphone connected to the internet. In the beginning of each session the chair will inform you of the code to use. Go to www.menti.com, enter the code and Submit and then the button Ask a question. Enter your question in the text box and press Submit. If selected by the chair, the speaker will address your question. The same web address will be used for voting, in some of the sessions. Please save the link as a Favorite bookmark for easy access!

Cowrie

Surgical Schedule - Day 1 Thursday, December 1st

7:45 am

Opening Remarks Welcome from the Hosts

8:00 am

Face: Putting Your Best Face Forward! Chair: Tim Marten & Co-Chair: Lou Bucky

Transcutaneous Direct Brow Shaping vs Other Brow lifting Procedures - Giovanni Botti

Peri-Orbital Fat Grafting - A New Paradigm for Rejuvenation of the Eyelids - Tim Marten

Dark Circles and Under Eye Hollow: My Graduate Approach - Chia Chi Kao

Endobrows and Blephs: My tricks after 25 years - Brad Calobrace

Malar Festoons Challenges: Lifting, Excision, Microliposucion or Fat Grafting? Giovanni Botti Discussion

8:50 am

Face: Putting Your Best Neck Forward! Chair: Brad Calobrace & Co-Chair: Patrick Maxwell

Re-Do Facelift in Heavy Neck Patients - Eyal Gur

Analyze, Planning and Execution of Deep Neck Lift - Per Hedén

Superficial Neck Rejuvenation Utilizing Dilute Fat - Lou Bucky

Short Scar Neck Lift - Neck Lift Using a Submental Incision Only - Tim Marten

Discussion

9:40 am

Facelift Panel : A Deep Dive Into Deep Neck: Chair: Brad Calobrace & Co-Chair: Per Heden

Brad Calobrace, Per Heden, Lou Bucky, Tim Marten, Chia Chi Kao, Giovanni Botti Eyal Gur, Andrew Jacono

Coffee Break

10:00 am

Face: Facing the Facts about Facial Fat! Chair: Giovanni Botti & Co-Chair: Kamakshi Zeidler

10:30 am

Science of Fat Grafting! - Frederik Trojahn Koelle

How to use SVF, PRP and PRS in Facial Surgery - Per Hedén

Facial Fat Grafting All Day Everyday: Nano Micro and Macro - Kamakshi Zeidler

Discussion 17 Points of Pan-Facial Fat grafting - Chia Chi Kao

Cowrie

Surgical Schedule - Day 1 Thursday, December 1st

11:25 am

Face: Full disclosure – It Isn’t All Great All the Time! Chair: Pat Maxwell & Co-Chair: Eyal Gur

And the “Eyes” Have It, My Worst and Best Case! - Lou Bucky

Fat Grafting Complication - Lower Eyelid Irregularities After Fat Grafting and its Corrections - Tim Marten

Ponytail Evolution - Chia Chi Kao

Eyelid Disaster – How Did I Fix It? -Giovanni Botti

Discussion

12:30 pm 12:40 pm

Lunch Allergan Sponsored Workshop

Social Transformative Aesthetics: An intersection of social psychology, technology, and medical aesthetics. - Patricia Ogilvie, Berno Bucker, Jason Kelly, Jacques Van Der Meulen

12:40 pm

Hydrafacial Sponsored Workshop

Combined Session - Surgical and Non-Surgical Current and Future Perspectives in Aesthetics: Chair: Per Heden & Co-Chair: Shino Bay 10 things Non-Surgical Experts Need to Know About Surgery - Per Hedén

1:30 pm

10 things Non-Surgical Experts Need to Know About Non-Surgery - Patricia Ogilvie

When Does Your Patient Need To “See the Knife”? - Shino Bay Aguilera

“After the Knife”: How To Maintain a Patient with Non-Surgical Procedures After Surgery - Brad Calobrace Enhancing Surgical Outcomes with Non-Surgical Treatments - Kamakshi Zeidler

Discussion

2:30 pm

Current and Future Perspectives in Aesthetics: Industry Panel Chair: Per Heden & Co-Chair: Brad Calobrace

Sientra Representative - Ron Menezes

Motiva Representative - JJ Chacon

Galderma Representative - Silvina Nordenstohl

Mentor Representative - Joseph Matton Allergan Representative - Jeffrey Ehrhardt

Discussion

3:30 pm 4:00 pm

Coffee Break

BTS Cup: USA vs Europe Chair: Yoav Barnea & Co-Chair: Shino Bay

TEAM US : Kamakshi Zeidler- MIchelle Henry - Lou Bucky- Brad Calobrace TEAM EUROPE : Ofir Artzi - Per Hedén - Patricia Ogilvie - Giovanni Botti

5:00 - 8:30 pm

Galderma Sponsored Workshop - The AART of GAIN

See Non-Surgical program for details

Surgical Schedule - Day 2 Friday, December 2nd

7:45 am

Face: Putting Your Best Face Forward! Chair: Eyal Gur & Co-Chair: Per Heden

Extended Deep Plane Facelift for Maximal Mid-Face and Neck Contouring - Andrew Jacono High SMAS Facelift - Simultaneous Lifting of the Mid-face, Cheek and Jawline - Tim Marten Ponytail technique for facial beautification and rejuvenation - Chia Chi Kao

Power of SMAS Lift: It’s All In the Vector! - Lou Bucky

Facial Panel: How Would you Approach This Case? Chair: Per Heden & Co-Chair: Brad Calobrace Male Facelifts: How It Is Different Than Female? - Andrew Jacono Discussion

9:00am

Lou Bucky, Tim Marten, Giovanni Botti, Andrew Jacono, Chia Chi Kao, Eyal Gur

9:30 am

Breast Session: Honoring Michael Scheflan and John Tebbett Chair: Per Heden & Co-Chair: Patrick Maxwell

Yoav Barnea, William Adams, Steven Tietelbaum

10:30 am 10:00 am

Coffee Break

Breast Session: Fat Grafting the Breast Chair: Caroline Glicksman & Co-Chair: Craig Layt

Will Culturing of ADRC Have a Place in Future Fat Grafting? - Frederik Trojahn Koelle Fat Grafting in Augmentation with Implants, Instead of Implants and After Implant Removal - Kamakshi Zeidler

What Works and Doesn’t Work in Fat Grafting - William Adams

Discussion

11:00 am

Breast Session: Belt and Suspenders: Soft Tissue Support Chair: Steven Tietelbaum & Co-Chair: Yoav Barnea Is There Still a Role for ADM in Aesthetic Breast - Allen Gabriel

Optimizing Outcomes with P4HB Mesh Support - William Adams

Current Algorithm for Pocket Control and Use of Soft Tissue Support - Brad Calobrace

PDO Mesh in Primary Breast - Sean Kileshadi

Discussion

11:45 am

KEYNOTE: Optimizing Revisional Breast Surgery Outcomes Patrick Maxwell Advancing Breast Aesthetics: Leveraging Consumer Feedback to Move the Category Forward - Joe Matton

12:05 am

12:15 pm 12:40 am

Lunch

Mentor Sponsored Workshop

BOOSTing innovation to achieve optimal outcomes - Chair: Krasi Hristoz Panel: WIlliam Adams, Brian Thorton, Brad Calobrace

Surgical Schedule - Day 2 Friday, December 2nd

1:30 pm

Breast: Hot Topics in Breast Implant Surgery Chair: Kamakshi Zeidler & Co-Chair: Adam Rubenstein ASERF Research on BII: From Hype to Science! - Caroline Glicksman

How I Talk to My BII Patients - Mindi Haws

The Texture Migration to a new bioengineered smooth Nanosurface - Giovanni Botti

Total/Enbloc Capsulectomy in BII Patients – Surgical Technique - Eyal Gur

Breast Panel: Navigating Breast Implant Issues Chair: Patrick Maxwell & Co-Chair: Craig Layt Managing the Textured Patient - Yoav Barnea How to analyze BII Research - Steven Tietelbaum Breast Surveillance with Ultrasound - William Adams

2:50 pm

Caroline Glicksman, Steven Tietelbaum, Yoav Barnea, Brad Calobrace, Bill Adams Mindy Haws

3:45 pm 3:15 pm

Coffee Break

Breast : Pitfalls and Windfalls Chair: William Adams & Co-Chair: Mindy Haws

Why the Periareolar Incision Should be Abandoned - Steven Tietelbaum

IMF Classification: Optimizing Outcomes and Avoiding Problems! - Craig Layt

Transitioning from Texture to Smooth implants - Caroline Glicksman

Capsular Contracture: Can We Do Better? - Yoav Barnea Discussion

4:35 am

Breast: To Implant or Not to Implant! That is the Question! Chair: Mindy Haws & Co-Chair: Frederik Trojahn Koelle Motiva FDA Trial: 2 Year Breast Augmentation Cohort Data - Caroline Glicksman

Mastopexy: Techniques for Every Season & Every Reason - Kamakshi Zeidler

Augmentation Mastopexy: Planning and Performance for Predictability - Craig Layt Alexandra Breast Lift : Circumareolar Mastopexy with Internal Lift -Chia Chi Kao A Plea for Lower Profile Implants - Brad Calobrace Maintaining Upper Pole Fullness in Mastopexy And Reductions - Per Hedén Discussion

5:45 pm

Final Remarks

6:00 pm

Cocktail Reception Sponsored by Allergan Aesthetics

Surgical Schedule - Day 3 Saturday, December 3rd

LOOK-LIVE Surgery Day tm

7:30 am

Facial Surgery Chair: Lou Bucky & Co-Chair: Brad Calobrace

Look Live Surgery: Extended Deep Plane, Posterior Platysmaplasty - Andrew Jacono & Per Heden Look Live Surgery: Difficult Deep Neck- Tim Marten & Lou Bucky

Look Live Surgery: Xact Facelift - Lou Bucky & Per Heden

9:45 am

Look Live - Face Panel - Lou Bucky, Tim Marten, Andrew Jacono, Per Hedén, Eyal Gur, & Giovanni Botti

10:00 am 10:30 am

Breast Surgery Chair: William Adams & Co-Chair: Yoav Barnea

Look Live Surgery: Secondary Augmentation Mastopexy with Mentor MGX and Mesh Support - Per Hedén & Yoav Barnea Look Live Surgery: Management of Textured Implant and Capsular Contracture with Mesh Support - William Adams & Brad Calobrace Look Live Surgery: Secondary Breast Surgery with Mastopexy and Allergan Implant Exchange - Brad Calobrace & Caroline Glicksman Look Live - Breast Panel - Caroline Glicksman, Brad Calobrace, Per Heden, William Adams, Yoav Barnea

12:00 pm

12:30 pm 1:00 pm

Lunch

Sientra Sponsored Workshop

Transforming the art and science of fat transfer - Moderators: Mindy Haws & Blaine Hamilton. Panel: Brad Calobrace, Dan DelVecchio, Miguel Medina

2:00 pm

Breast & Body Surgery Chair: Per Heden & Co-Chair: Caroline Glicksman

Look Live Surgery: Augmentation Mastopexy with Motiva Ergonomic II- Giovanni Botti & Brad Calobrace Look Live Surgery: Aveli Cellulite Treatment - Craig Layt & Kamakshi Zeidler Breast & Body Panel - Giovanni Botti, William Adams, Craig Layt, Kamakshi Zeidler Look Live Surgery: Augmentation Mastopexy with Sientra’s new low profile plus implant - Brad Calobrace & Mindy Haws Look Live Surgery: Breast Augmentation with Mentor Boost Implant - William Adams & Brad Calobrace

3:15 pm

4:00 pm 3:30 pm

Coffee Break

Facial Surgery Chair: Per Heden & Co-Chair: Eyal Gur

Extended Blepharoplasty to Correct Maylar Bags with Direct Browlift - Giovanni Botti Look Live Surgery: Facial Rejuvenation with Ponytail Technique - Chia Chi Kao, Francisco Bravo

4:45 pm 5:00 pm

Face & Eyes Panel - Chia Chi Kao, Giovanni Botti, Brad Calobrace

Final remarks

Non-Surgical Schedule - Day 1 Thursday, December 1st

7:45 am

Opening Remarks Welcome from the Hosts

7:55 am

Trends in Aesthetics Chair: Raj Acquilla & Co-Chair: Patricia Ogilvie

Off the Face - What are people doing to the body non-surgical - Shino Bay

Topical exosomes & Aestetics: Advanced Science for Supirior Resulis - Jordan Plews

Trends in Asia - Ting Song

Changing trends in filler treatments - Tapan Patel

Discussion

9:05 am

Fillers Session 1 Chair: shino Bay & Co-Chair: Raj Acquilla Hyper Dilute CAHA (3 Point Technique) - Shino Bay

4D periorbital rejuvenation - Tom Van Eijk

Pillow Face Syndrome - Tapan Patel

Happiness in the Absence of Complications: How to be proactive in decreasing the risk of adverse reactions in aesthetics - Lori Robertson

Discussion

Coffee Break

10:55 am 10:35 am 10:05 am

Fillers Session 2 Chair: shino Bay & Co-Chair: Raj Acquilla Keynote: The Psycho-Social Effect of Aging - Shino Bay

Future of Aesthetic Medicine- Jenifer Pearlman

Asian Patients - Ting Song

Discussion

2cc Challenge: Faculty will each have a patient and will have 10 minutes to use 2ccs to improve the patient’s appearance. Patricia Ogilvie, Michelle Henry, Raj Acquilla

Discussion

12:15 pm 12:40 pm 12:40 pm

Lunch in the Exhibitor Hall

Industry-Sponsored Workshop: Hydrafacial Industry-Sponsored Workshop: Allergan Social Transformative Aesthetics: An intersection of social psychology, technology, and medical aesthetics. - Patricia Ogilvie, Berno Bucker, Jason Kelly, Jacques Van Der Meulen

Cowrie

Non-Surgical Schedule - Day 1 Thursday, December 1st

1:30 pm

10 things Non-Surgical Experts Need to Know About Non-Surgery - Patricia Ogilvie

When Does Your Patient Need To “See the Knife”? - Shino Bay Aguilera

“After the Knife”: How To Maintain a Patient with Non-Surgical Procedures After Surgery - Brad Calobrace Enhancing Surgical Outcomes with Non-Surgical Treatments - Kamakshi Zeidler

Discussion

2:30 pm

Current and Future Perspectives in Aesthetics: Industry Panel Chair: Per Heden & Co-Chair: Brad Calobrace

Sientra Representative - Ron Menezes

Motiva Representative - JJ Chacon

Galderma Representative - Silvina Nordenstohl

Mentor Representative - Joseph Matton Allergan Representative - Jeffrey Ehrhardt

Discussion

3:30 pm 4:00 pm

Coffee Break

BTS Cup: USA vs Europe Chair: Yoav Barnea & Co-Chair: Shino Bay

TEAM US : Kamakshi Zeidler- MIchelle Henry - Lou Bucky- Brad Calobrace TEAM EUROPE : Ofir Artzi - Per Hedén - Patricia Ogilvie - Giovanni Botti

5:00 - 8:30 pm

Galderma Sponsored Workshop - The AART of GAIN

An educational journey through assesment, anatomy, rehology, and reconstruction and treatment planning with live injection technique demonstration of the Galderma injection portfolio Presenters: Raj Acquilla, Kay Durairaj, Andreas Nikolis, Sachin Shridharani, Tom Van Eijk, Shino Bay

Non Surgical Schedule - Day 2 Friday, December 2nd

8:00 am

Combination Therapy: Chair: Shino Bay & Co-Chair: Michelle Henry Questions to the audience Creating beauty with combination therapy - Kay Durairaj Combinations therapy using Microneedeling for the treatment of different scars - Ofir Artzi Pigmentary alteration mono therapy VS combine approch - Michelle Henry

Discussion

8:50 am

Dermatonutrigenomics: Nourishing Skin According to Genes Sarah Mahdavi

9:10 am

Scar management Chair: Ofir Artzi & Co-Chair: Patricia Ogilvie

Scar Management with Microneedling - Gabriela Cassabona Combination approach to scar management - Ofir Artzi Chemical Injury burns - Tapan Patel

Discussion

10:00 am

Coffee break in exhibition area

10:30 am

My best case (I need a miracle) Chair: Raj Acquilla & Co-Chair: Tapan Patel Adam Rubenstein

Patricia Ogilvie

Lori Robertson Mary Lupo

Discussion

11:05 am

Anatomy, The Trinity of Beauty Chair: Raj Acquilla & Co-Chair: Tapan Patel

Chin - Patricia Ogilvie

Ramus - Shino Bay Aguilera

Zygoma - Raj Acquilla “I am overfilled, I look masculine.” What to do? - Chia Chi Kao

Discussion

Non Surgical Schedule - Day 2 Friday, December 2nd

12:00 pm 12:45 pm

Lunch in the exhibition area - Sponsored By Galderma Industry sponsored lunch workshop- Allergan Sneak Peek Juvéderm VOLUX for Jawline Definition - Patricia Ogilvie

1:30 pm

Botulinum Toxin Chair: Tapan Patel & Co-Chair: Ting Song Saftey and Efficacy of Prabotulinumtoxin A in the Teatment of Glabellar Lines in Millennials VS Non Millennials. - Rui Avelar My safe and natural approch of neurotoxins for asian patients - Ting Song Pre-juvenation, neurotoxin for the millenial patient - Ofir Artzi Facial rejuvenation of the upper face with neurotoxin (female patient) - Patricia Ogilvie Facial rejuvenation of the upper face with neurotoxin (male patient) - Tapan Patel Neurotoxin adjustment with the passing of time (how do you adjust technique as your patients get older) - Shino Bay

Discussion

Clinical real-life scenarios Chair: Mary Lupo & Co-Chair: Raj Acquilla

2:45 pm

Liquid Rinoplasty Consultation: How to say “NO” as a physician if you aren’t comfortable with a procedure on a patient that you’ve had for years. - Patricia Ogilvie and Ofir Artzi Shino wants to Transition and Adam needs to navigate the conversation Shino Bay and Adam Rubenstein Russian Lips: When enough is engouh Jenifer Pearlman and Mary Lupo

3:15 pm

Coffee break in the exhibition area

3:45 pm

Complications Chair: Mary Lupo & Co-Chair: Raj Acquilla

Diagnosis, Management, & Avoidance of injectable complications - Andreas Nickolis Long term management of nose arterial occlusion, skin necrosis and scarring after filler injection - Ofir Artzi If you haave never had a comlications,you are not inject enough - Mary Lupo

4:45 pm

Social Media + Marketing Chair: Shino Bay & Co-Chair: Brad Calobrace

Social Media Responsibility - Shino Bay

Attract more patients through marketing funnels - Jared Rohrer Building a franchise - Brad Calobrace

Discussion

6:00 pm

Cocktail Reception Sponsored by Allergan

Non Surgical Schedule - Day 3 Saturday, December 3rd

9:00 am

Microneedling ,Threads, Fillers Chair: Shino Bay & Co-Chair: Doris Day

Multiple L.I.T technique to battle skin laxity - Ofir Artzi Lower Face Busso Combination Technique - Mariano Buso Combination Threads + CAHA - Shino Bay

Panel discussion Skin qulity improvement:what can we achieve with microneedling - Gabriela Casabona

10:00 am

Coffee break in exhibition area

Aesthetic Technology Chair: Shino Bay & Co-Chair: Doris Day

10:30 am

Revolutionary Ultrasound Technology for Fine Lines and Wrinkles, Brad Calobrace & Adam Rubenstein Bioregenerative medical microneedling - Shino Bay Three Devices That I Can’t Live Without - Ofir Artzi A lasting solution for Cellulite,a foundational component of lower body rejuvenation - Craig Layt Discussion Injectables for younger males and females: Enhancement Chair: Patricia Ogilvie & Co-Chair: Heidi Waldorf Injectable fillers techniques for the young african american patient - Michelle Henry Male filler (HD-sculpt with CaHa) - Shino Bay Aguilera

11:30 am

Filler Consultation - Heidi Waldorf Male neurotoxin - Ting Song Female neurotoxin - Patricia Ogilvie Panel discussion

12:30 pm 1:30 pm

Lunch in the exhibition hall

Injectables for middle aged: PRE-juvenation Chair: Mary Lupo & Co-Chair: Adam Rubenstein Five tenets of aging - Kay Durairaj Male Filler - Shino Bay Female Filler - Tapan Patel Male neurotoxin, Adam Rubenstein

Panel discussion Female neurotoxin, Heidi Waldorf

Non Surgical Schedule - Day 3 Saturday, December 3rd

2:30 pm

Injectables for the mature male and female: RE-juvenation Chair: Ofir Artzi & Co-Chair: Patricia Ogilvie Male filler - Shino Bay

Female filler - Michelle Henry Male neurotoxin - Chia Chi Kao Female neurotoxin - Ting Song

Coffee Break Panel discussion

3:30 pm

4:00 pm

Thinking Outside the Box Chair: Mary Lupo & Co-Chair: Adam Rubenstein Desired Facial Shapes and How to Achieve- Mary Lupo The dawn of a new ERA - Shino Bay Looking at It from the Outside: How Important is Facial Symmetry? - Patricia Ogilvie Panel discussion

4:50 pm

Closing Remarks

THANK YOU to our wonderful 2022 sponsors Dysport® is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. HIGHLY SATISFIED PATIENTS You can have confidence that Dysport will deliver.

97% of users § thought their results looked natural 6 months after treatment (1,†)

FAST ACTING RESULTS Users § see results in 2-3 days (2-4,*)

LONG LASTING RESULTS

95% of users § were satisfied with just 2 Dysport treatments per year (1,†)

§ Users= clinical trial subjects. * A secondary endpoint based on Kaplan-Meier estimates of cumulative rate of time to onset of response. The median time to onset of response was 3 days in GL-1 (Dysport 55/105 [52%], Placebo 3/53 [6%] and GL-2 (Dysport 36/71 [51%], Placebo 9/71 [13%]), and 2 days in GL-3 (Dysport 110/200 [55%], Placebo 4/100 [4%]). † Subject-reported at 12 months (N=120) after two treatments six months apart in a phase IV, mulitcenter, prospective study. Indication Dysport® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. Important Safety Information What is the most important information you should know about Dysport Dysport the body away from the injection site. Symptoms can happen hours to weeks after injection and may include swallowing and breathing problems, loss of strength and muscle weakness all over the body, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, or loss of bladder control. Swallowing and breathing problems can be life threatening and there have been reports of death. You are at the highest risk if these problems are pre-existing before injection. Do not have Dysport treatment if you: are allergic to Dysport or any of its ingredients (see the end of the Medication Guide for a list of ingredients), are allergic to cow’s milk protein, had an allergic reaction to any other botulinum toxin product, such as Myobloc®, Botox®, or Xeomin®, have a skin infection at the planned injection site, under 18 years of age, or are pregnant or breastfeeding. The dose of Dysport is not the same as the dose of any other botulinum toxin product and cannot be compared to the dose of any other product you may have used. such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis, ing. Serious allergic reactions have occurred with the use of Dysport . Dry eye has also been reported. Tell your doctor about all of your medical conditions, including if you have surgical changes to your face, very weak muscles in the treatment area, any abnormal facial change, injection site

Actual patients. Individual results may vary.

inflammation, droopy eyelids or sagging eyelid folds, deep facial scars, thick oily skin, wrinkles that can’t be smoothed by spreading them apart, or if you are pregnant or breastfeeding or planning to become pregnant or breastfeed. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products. Using Dysport with certain other Do not start any new medicines while taking Dysport without talking to your doctor first. Especially tell your doctor if you: have received any other botulinum toxin product, such as Myobloc® (rimabotulinumtoxinB), Botox® (onabotulinumtoxinA), or Xeomin® (incobotulinumtoxinA), in the last four months or any in the past (be sure your doctor knows exactly which product you received, have recently received an antibiotic by injection, take muscle relaxants, take an allergy or cold medicine, or take a sleep medicine.

respiratory tract infection, eyelid swelling, eyelid drooping, sinus

inflammation, and nausea. Ask your doctor if Dysport is right for you.

www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information including Medication Guide at DysportUSA.com. REFERENCES:

1. Data on file. 43USD1802 Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2020. 2. Data on file. MA-Y-97-52120-085 (GL-2) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007 3. Data on file. GL-Y-97-52120-719 (GL-1) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007. 4. Data on file. GL-Y-97-52120-718 (GL-3) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.

Real-World Evidence Shows Low Rupture Rates of MENTOR ® MemoryGel ® Breast Implants

Mentor global complaint rates and post-approval study report long-term low rupture ra

Mentor global complaint rates and post-approval study report long-term low rupture rates

Mentor Global Rupture Complaint Rate 1 (over 16 years ) a

6 M+ IMPLANTS

0.6 %

MemoryGel devices used for Augmentation and Reconstruction

MemoryGel ® Post-Approval Study Reoperations Due to Rupture b,2 (over 10 years )

700 U.S. CENTERS c

~ 6,700 PATIENTS c

0.8 %

MemoryGel devices used for Primary Augmentation

Latest independent research with high resolution ultrasound (HRUS) consistently $ +($É+( +Êł È É d,3 (implanted up to 20 years ) e

9 U.S. CENTERS

608 IMPLANTS e

9 U.S. CENTERS

608 IMPLANTS e

6.5 %

MemoryGel and MemoryShape ® Breast Implants used for Augmentation and Reconstruction

a MENTOR® MemoryGel Complaint Data stats: U.S. from Jan 2006 through Dec 2021, EMEA/ LATAM / Canada/ APAC from Jan 2011 through Dec 2021. b : Ê+ É$$ ÊÈ Ç+ÊÇ + É+Ê( (É$ÈÊłÈÉ$ É & +$+ + É+Ê c Number of patients and centers that participated in the re-operation phase of the study; overall, 74.1% of women in the re-operation phase completed their 10 year follow-up. Among these ~6,700 patients, 944 women underwent 1,748 total re-operations, of which rupture was the primary reason for 14 of those re-operations. d 8.7% (53/608) of MENTOR Implants were evaluated as suspected ruptures based on HRUS. For the entire study cohort, 82 women had suspected ruptures, 40 of whom were explanted. Upon explantation, 25% of the suspected ruptures were found intact, giving a 25% false-positivity to the HRUS detection accuracy. This calculation assumes that the 25% false positivity was evenly distributed across different manufacturers’ devices and would persist if the remaining 42 women were explanted and that there would be no false negatives. e Including MemoryGel and MemoryShape Breast Implants implanted between Jan 2000 and Dec 2015, HRUS performed between April 2019 and March 2020. a MENTOR® MemoryGel Complaint Data stats: U.S. from Jan 2006 through Dec 2021, EMEA/ LATAM / Canada/ APAC from Jan 2011 through Dec 2021. b : Ê+ É$$ ÊÈ Ç+ÊÇ + É+Ê( (É$ÈÊłÈÉ$ É & +$+ + É+Ê c Number of patients and centers that participated in the re-operation phase of the study; overall, 74.1% of women in the re-operation phase completed their 10 year follow-up. Among these ~6,700 patients, 944 w underwent 1,748 total re-operations, of which rupture was the primary reason for 14 of those re-operations. d 8.7% (53/608) of MENTOR Implants were evaluated as suspected ruptures based on HRUS. For the entire study cohort, 82 women had suspected ruptures, 40 of whom were explanted. Upon explantation, 25% suspected ruptures were found intact, giving a 25% false-positivity to the HRUS detection accuracy. This calculation assumes that the 25% false positivity was evenly distributed across different manufacturers’ dev persist if the remaining 42 women were explanted and that there would be no false negatives. e Including MemoryGel and MemoryShape Breast Implants implanted between Jan 2000 and Dec 2015, HRUS performed between April 2019 and March 2020. WARNING: • Breast implants are not considered lifetime devices. The longer people have them, the greater the chances are that they will develop complications, some of which will require more surgery. • Breast implants have been associated with the development of a cancer of the immune system called breast implant-associated anaplastic large cell lymphoma Z15-c-ABA[D $ ÉÊ + $+ ++Ê&ÊÉÊ$( ) È É$ÉÊ$ ÉÊ$++ ÉÊ$É + Ç É$É Ê+(ÈłÊÈh+ patients have died from BIA-ALCL. • Patients receiving breast implants have reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement. • Breast implants have been associated with the development of a cancer of the immune system called breast implant-associated anaplastic large cell lym Z15-c-ABA[D $ ÉÊ + $+ ++Ê&ÊÉÊ$( ) È É$ÉÊ$ ÉÊ$++ ÉÊ$É + Ç É$É Ê+(ÈłÊÈh+ patients have died from BIA-ALCL. • Patients receiving breast implants have reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmun diseases and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of sym when the implants are removed without replacement. WARNING: • Breast implants are not considered lifetime devices. The longer people have them, the greater the chances are that they will develop complications, some will require more surgery.

D $ÉÉÊÈÈ$ +Ê+ 8Ê+ 1 É$5ÉÊ2" $É $ È+ $ $ÉÊÈd+ $ É $ É +"ÈÊ + É+Ê+ÉÊ$É+ $%$ÉÊÈÊł$+ È" + +$ $Ê + ÉÊÈÉÊÊ $ łÈÊÉ +"ÈÉÊÇ+ +"ÈÈ&8Ê+ j+ È(ÈAAB D $ÉÉÊÈÈ$ +Ê+ 8Ê+ 1 É$5ÉÊ2" $É $ È+ $ $ÉÊÈd+ $ É $ É +"ÈÊ + É+Ê+ÉÊ$É+ $%$ÉÊÈÊł$+ È" + ÉÊÈÉÊÊ $ łÈÊÉ +"ÈÉÊÇ+ +"ÈÈ&8Ê+ j+ È(ÈAAB

Real-World Evidence Shows Low Rupture Rates of MENTOR ® MemoryGel ® Breast Implants

World Evidence Shows Low Rupture Rates of NTOR ® MemoryGel ® Breast Implants

Summary of Real-World Evidence

y of Real-World Evidence

Global Complaint Analysis Mentor Complaints Analysis 1

Global Complaint Analysis Mentor Complaints Analysis 1 Source

Multicenter Studies

Single Center Studies

Multicenter Studies

Single Center Studies

Salzman 3P Short 2P (MemoryGel Post-Approval Study)

Short 2P (MemoryGel Post-Approval Study)

Salzman 3P

Maxwell 4R

Collis 5P

Maxwell 4R

Collis 5P

urce

0.6%

0.8%

6.5%

1.6%

11.8%

0.6%

0.8%

6.5%

1.6%

11.8%

Rate

ate

Type of Rate

B+Êł È;

Re-ops Due to Rupture b

B+Êł È d Rupture

B+Êł È;

of Rate

B+Êł È;

Re-ops Due to Rupture b

B+Êł È d Rupture

B+Êł È;

Multicenter (>700 in Re-op phase c ) ~6,700 Patients in Re-op Phase c

Multicenter (>700 in Re-op phase c ) ~6,700 Patients in Re-op Phase c N/A

Centers

Multicenter (9)

Single

nters

N/A

Multicenter (9)

Single

608 Implants e

191 Patients

149 Patients

Sample Size

6 Million+ Implants

608 Implants e

191 Patients

149 Patients

le Size

6 Million+ Implants

Augmentation and Reconstruction

Augmentation and Reconstruction Cohort(s)

Augmentation and Reconstruction

Primary Augmentation

Primary Augmentation Primary Augmentation

ort(s)

Primary Augmentation

Primary Augmentation Primary Augmentation

10 Years

13 Years

N/A Duration of Follow-up

N/A

10 Years

Up to 20 Years e

10 Years

13 Years

f Follow-up

10 Years

Up to 20 Years e

2007-2019

2000-2020

~1990s to Early 2000s 2006-2019

~1990s to Early 2000s

Study Timeframe

2006-2021 a

2007-2019

2000-2020

2006-2019

meframe

2006-2021 a

Implant Patient or Implant Level Rate

mplant Level ate

Implant

Patient

Implant

Patient

Implant

Patient

Implant

Patient

Implant

No Scheduled Imaging?

HRUS

MRI

d Imaging?

HRUS

MRI

Where Conducted?

Worldwide

U.S.

onducted?

Worldwide

U.S.

MemoryGel, MemoryShape

MemoryGel ® SILTEX only

Devices

MemoryGel

MemoryGel ® SILTEX only

vices

MemoryGel

P = prospective study, R = retrospective study

study, R = retrospective study

a is passively collected through an internal system and cannot be determined from this reporting system alone due to potential under-reporting, duplicate reporting of events, and the lack of ,foȗeöljļŞƌAöīŞöÎŤūJljśīÎijūŤÎŞöéÎêĨöðéƌÎċŞööīĕċöūĕljöśŞļðŰêūŞöśīÎêöljöijūśļīĕêƌūĒÎūŞöŝŰĕŞöŤūĒöśÎūĕöijūūļŞöśļŞūĕijêĕðöijêöļċŞŰśūŰŞöĕijļŞðöŞūļéöijöƞūċŞļljūĒöśļīĕêƌǂĒļŞū REFERENCES 1. Complaint data is passively collected through an internal system and cannot be determined from this reporting system alone due to potential under-reporting, duplicate reporting of events, and the lack of ĕijċļŞljÎūĕļijǂe,foȗeöljļŞƌAöīŞöÎŤūJljśīÎijūŤÎŞöéÎêĨöðéƌÎċŞööīĕċöūĕljöśŞļðŰêūŞöśīÎêöljöijūśļīĕêƌūĒÎūŞöŝŰĕŞöŤūĒöśÎūĕöijūūļŞöśļŞūĕijêĕðöijêöļċŞŰśūŰŞöĕijļŞðöŞūļéöijöƞūċŞļljūĒöśļīĕêƌǂĒļŞū ts from the MemoryGel Post-approval Study Plast Reconstr Surg Glob Open. 2021 Mar 26;9(3):e3402. Results from the MemoryGel Post-approval Study. Plast Reconstr Surg Glob Open. 2021 Mar 26;9(3):e3402. KK, et al. Results from the MemoryGel Post-approval Study Plast Reconstr Surg Glob Open. 2021 Mar 26;9(3):e3402. 2. Short KK, et al. Results from the MemoryGel Post-approval Study. Plast Reconstr Surg Glob Open. 2021 Mar 26;9(3):e3402. lent Rupture of Silicone Gel Breast Implants: High-Resolution Ultrasound Scans and Surveys of 584 Women. Plast Reconstr Surg. 2022 Jan 1;149(1):7-14. ÎīǂÎċöūƌÎijð,ƙöêūĕƅöijöŤŤļċĕīĕêļijöAöīǔ@ĕīīöðŞöÎŤūJljśīÎijūŤĕijŞĕljÎŞƌŰČljöijūÎūĕļijÎūĕöijūŤǂöŤūĒöūŰŞČYǂƧƥƧƦeÎƌƦƭǇƩƦǐƫǑƼfƨƧƮǔfƨƨƪǂ Magnetic resonance imaging and explantation investigation of long-term silicone gel implant integrity. Plast Reconstr Surg. 2007 Oct;120(5):MG 1401-1406. 3. Salzman MJ. Silent Rupture of Silicone Gel Breast Implants: High-Resolution Ultrasound Scans and Surveys of 584 Women. Plast Reconstr Surg. 2022 Jan 1;149(1):7-14. 4. eÎƋƆöīī&ƽöūÎīǂÎċöūƌÎijð,ƙöêūĕƅöijöŤŤļċĕīĕêļijöAöīǔ@ĕīīöðŞöÎŤūJljśīÎijūŤĕijŞĕljÎŞƌŰČljöijūÎūĕļijÎūĕöijūŤǂöŤūĒöūŰŞČYǂƧƥƧƦeÎƌƦƭǇƩƦǐƫǑƼfƨƧƮǔfƨƨƪǂ 5. Collis N, et al. Magnetic resonance imaging and explantation investigation of long-term silicone gel implant integrity. Plast Reconstr Surg. 2007 Oct;120(5):MG 1401-1406. ation: ŞĕļŞūļŰŤöƽŞöċöŞūļūĒöĕijŤūŞŰêūĕļijŤċļŞŰŤöŤŰśśīĕöðƆĕūĒūĒĕŤðöƅĕêöċļŞĕijðĕêÎūĕļijŤƽêļijūŞÎĕijðĕêÎūĕļijŤƽŤĕðööƙöêūŤƽƆÎŞijĕijČŤÎijðśŞöêÎŰūĕļijŤǂ restricts this device to sale by or on the order of a physician. Information: MENTOR® MemoryGel® Breast Implants are indicated for breast augmentation in women at least 22 years old or for breast reconstruction. Breast should not be performed in women with active infection anywhere in their body with existing cancer or pre-cancer of their breast who have not received adequate ose conditions or are pregnant or nursing. Breast implants are not lifetime devices and breast implantation is not necessarily a one-time surgery. The chance of plications increases over time. The most common complications with the MemoryGel® Breast Implants include reoperation, capsular contracture, asymmetry, and ƆöŞŞĕŤĨļċêļljśīĕêÎūĕļijĕŤŞŰśūŰŞöǂĒöĒöÎīūĒêļijŤöŝŰöijêöŤļċÎŞŰśūŰŞöðŤĕīĕêļijöČöīǔƞīīöðéŞöÎŤūĕljśīÎijūĒÎƅöijļūéööijċŰīīƌöŤūÎéīĕŤĒöðǂeJŤêŞööijĕijČŤÎŞö hree years after initial implant surgery and then every two years after to detect silent rupture. Breast implants are also associated with the risk of breast implant- lastic large cell lymphoma (BIA-ALCL), an uncommon type of lymphoma. An individual’s risk of developing BIA-ALCL with MENTOR® Breast Implants is low ĕðöijêöļċƆļŞīðƆĕðöêÎŤöŤǂÎūĕöijūŤŤĒļŰīðŞöêöĕƅöÎêļśƌļċJljśļŞūÎijūJijċļŞljÎūĕļijċļŞŰČljöijūÎūĕļijÎūĕöijūŤÎéļŰūe,foȗeöljļŞƌAöīȗĕīĕêļijöAöīǔ@ĕīīöð ļŞJljśļŞūÎijūJijċļŞljÎūĕļijċļŞöêļijŤūŞŰêūĕļijÎūĕöijūŤÎéļŰūe,foȗeöljļŞƌAöīȗĕīĕêļijöAöīǔ@ĕīīöðŞöÎŤūJljśīÎijūŤǂÁļŰŞśÎūĕöijūijööðŤūļŞöÎðÎijðŰijðöŞŤūÎijð ŞöČÎŞðĕijČūĒöŞĕŤĨŤÎijðéöijöƞūŤļċéŞöÎŤūĕljśīÎijūŤƽƆĕūĒÎijļśśļŞūŰijĕūƌūļêļijŤŰīūƆĕūĒƌļŰśŞĕļŞūļðöêĕðĕijČļijŤŰŞČöŞƌǂ@ļŞðöūÎĕīöðĕijðĕêÎūĕļijŤƽêļijūŞÎĕijðĕêÎūĕļijŤƽ êÎŰūĕļijŤÎŤŤļêĕÎūöðƆĕūĒūĒöŰŤöļċeöljļŞƌAöīȗŞöÎŤūJljśīÎijūŤǂīöÎŤöŞöċöŞūļūĒöJijŤūŞŰêūĕļijŤċļŞ¤ŤöǐJ@¤ǑśŞļƅĕðöðƆĕūĒöÎêĒśŞļðŰêūƽļŞļijīĕijöÎūƆƆƆǂ m. Important Safety Information: MENTOR® MemoryGel® Breast Implants are indicated for breast augmentation in women at least 22 years old or for breast reconstruction. Breast implant surgery should not be performed in women with active infection anywhere in their body with existing cancer or pre-cancer of their breast who have not received adequate treatment for those conditions or are pregnant or nursing. Breast implants are not lifetime devices and breast implantation is not necessarily a one-time surgery. The chance of developing complications increases over time. The most common complications with the MemoryGel® Breast Implants include reoperation, capsular contracture, asymmetry, and éŞöÎŤūśÎĕijǂīļƆöŞŞĕŤĨļċêļljśīĕêÎūĕļijĕŤŞŰśūŰŞöǂĒöĒöÎīūĒêļijŤöŝŰöijêöŤļċÎŞŰśūŰŞöðŤĕīĕêļijöČöīǔƞīīöðéŞöÎŤūĕljśīÎijūĒÎƅöijļūéööijċŰīīƌöŤūÎéīĕŤĒöðǂeJŤêŞööijĕijČŤÎŞö recommended three years after initial implant surgery and then every two years after to detect silent rupture. Breast implants are also associated with the risk of breast implant- associated anaplastic large cell lymphoma (BIA-ALCL), an uncommon type of lymphoma. An individual’s risk of developing BIA-ALCL with MENTOR® Breast Implants is low éÎŤöðļijūĒöĕijêĕðöijêöļċƆļŞīðƆĕðöêÎŤöŤǂÎūĕöijūŤŤĒļŰīðŞöêöĕƅöÎêļśƌļċJljśļŞūÎijūJijċļŞljÎūĕļijċļŞŰČljöijūÎūĕļijÎūĕöijūŤÎéļŰūe,foȗeöljļŞƌAöīȗĕīĕêļijöAöīǔ@ĕīīöð ŞöÎŤūJljśīÎijūŤļŞJljśļŞūÎijūJijċļŞljÎūĕļijċļŞöêļijŤūŞŰêūĕļijÎūĕöijūŤÎéļŰūe,foȗeöljļŞƌAöīȗĕīĕêļijöAöīǔ@ĕīīöðŞöÎŤūJljśīÎijūŤǂÁļŰŞśÎūĕöijūijööðŤūļŞöÎðÎijðŰijðöŞŤūÎijð ūĒöĕijċļŞljÎūĕļijŞöČÎŞðĕijČūĒöŞĕŤĨŤÎijðéöijöƞūŤļċéŞöÎŤūĕljśīÎijūŤƽƆĕūĒÎijļśśļŞūŰijĕūƌūļêļijŤŰīūƆĕūĒƌļŰśŞĕļŞūļðöêĕðĕijČļijŤŰŞČöŞƌǂ@ļŞðöūÎĕīöðĕijðĕêÎūĕļijŤƽêļijūŞÎĕijðĕêÎūĕļijŤƽ ƆÎŞijĕijČÎijðśŞöêÎŰūĕļijŤÎŤŤļêĕÎūöðƆĕūĒūĒöŰŤöļċeöljļŞƌAöīȗŞöÎŤūJljśīÎijūŤǂīöÎŤöŞöċöŞūļūĒöJijŤūŞŰêūĕļijŤċļŞ¤ŤöǐJ@¤ǑśŞļƅĕðöðƆĕūĒöÎêĒśŞļðŰêūƽļŞļijīĕijöÎūƆƆƆǂ mentorwwllc.com. Important information: ŞĕļŞūļŰŤöƽŞöċöŞūļūĒöĕijŤūŞŰêūĕļijŤċļŞŰŤöŤŰśśīĕöðƆĕūĒūĒĕŤðöƅĕêöċļŞĕijðĕêÎūĕļijŤƽêļijūŞÎĕijðĕêÎūĕļijŤƽŤĕðööƙöêūŤƽƆÎŞijĕijČŤÎijðśŞöêÎŰūĕļijŤǂ Caution: US law restricts this device to sale by or on the order of a physician. moryGel Complaint Data stats: U.S. from Jan 2006 through Dec 2021, EMEA/ LATAM / Canada/ APAC from Jan 2011 through Dec 2021. ÊÈ Ç+ÊÇ + É+Ê( (É$ÈÊłÈÉ$ É & +$+ + É+Ê ts and centers that participated in the re-operation phase of the study; overall, 74.1% of women in the re-operation phase completed their 10 year follow-up. Among these ~6,700 patients, 944 women otal re-operations, of which rupture was the primary reason for 14 of those re-operations. MENTOR Implants were evaluated as suspected ruptures based on HRUS. For the entire study cohort, 82 women had suspected ruptures, 40 of whom were explanted. Upon explantation, 25% of the s were found intact, giving a 25% false-positivity to the HRUS detection accuracy. This calculation assumes that the 25% false positivity was evenly distributed across different manufacturers’ devices and would ining 42 women were explanted and that there would be no false negatives. Gel and MemoryShape Breast Implants implanted between Jan 2000 and Dec 2015, HRUS performed between April 2019 and March 2020. a MENTOR® MemoryGel Complaint Data stats: U.S. from Jan 2006 through Dec 2021, EMEA/ LATAM / Canada/ APAC from Jan 2011 through Dec 2021. b : Ê+ É$$ ÊÈ Ç+ÊÇ + É+Ê( (É$ÈÊłÈÉ$ É & +$+ + É+Ê c Number of patients and centers that participated in the re-operation phase of the study; overall, 74.1% of women in the re-operation phase completed their 10 year follow-up. Among these ~6,700 patients, 944 women underwent 1,748 total re-operations, of which rupture was the primary reason for 14 of those re-operations. d 8.7% (53/608) of MENTOR Implants were evaluated as suspected ruptures based on HRUS. For the entire study cohort, 82 women had suspected ruptures, 40 of whom were explanted. Upon explantation, 25% of the suspected ruptures were found intact, giving a 25% false-positivity to the HRUS detection accuracy. This calculation assumes that the 25% false positivity was evenly distributed across different manufacturers’ devices and would persist if the remaining 42 women were explanted and that there would be no false negatives. e Including MemoryGel and MemoryShape Breast Implants implanted between Jan 2000 and Dec 2015, HRUS performed between April 2019 and March 2020.

wide LLC 2022 211347-220706

Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44 Page 45 Page 46 Page 47 Page 48 Page 49 Page 50 Page 51 Page 52 Page 53 Page 54 Page 55

Made with FlippingBook Digital Proposal Creator